Introduction to Modeling Informed Drug Development
Let's dive into the details surrounding Modeling Informed Drug Development. This module is part of the educational series “
Modeling Informed Drug Development Comprehensive Overview
Carolyn Cho, Merck & Co. January 27, 2022 MfPH Workshop on Endemic COVID-19: Mathematical Insights ... This lecture by Drs. Adekemi, Taylor, Rajesh Krishna and S.Y. Amy Cheung, Senior Directors of Integrated Roche pRED Clinical Pharmacology uses
Morten Nielsen, PhD. - The use of HLA class II antigen presentation prediction in the context of immunogenicity assessment of ...
Summary & Highlights for Modeling Informed Drug Development
- Jochem Gokemeijer, PhD. - Pre-clinical immunogenicity risk assessment tools and strategies for novel modalities.
- Dr. Mark R. Gasronguay, Founder and CEO of the Metrum Research Group, asks “why use
- This module is part of the educational series “
- Innovations in statistics, programming and data management are changing the very nature of clinical
- Peter Marks, MD. PhD. – Welcome Remarks.
That wraps up our extensive overview of Modeling Informed Drug Development.